Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer
eLife · 2025
DOI: 10.7554/elife.93921 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Tackhoon Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Materials Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Proto-Oncogene Proteins c-fyn, Jumonji Domain-Containing Histone Demethylases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Institute of Science and Technology.
Abstract (Originalsprache)
Tyrosine kinases play a crucial role in cell proliferation and survival and are extensively investigated as targets for cancer treatment. However, the efficacy of most tyrosine kinase inhibitors (TKIs) in cancer therapy is limited due to resistance. In this study, we identify a synergistic combination therapy involving TKIs for the treatment of triple negative breast cancer. By employing pairwise tyrosine kinase knockout CRISPR screens, we identify FYN and KDM4 as critical targets whose inhibition enhances the effectiveness of TKIs, such as NVP-ADW742 (IGF-1R inhibitor), gefitinib (EGFR inhibitor), and imatinib (ABL inhibitor) both in vitro and in vivo. Mechanistically, treatment with TKIs upregulates the transcription of KDM4 , which in turn demethylates H3K9me3 at FYN enhancer for FYN transcription. This compensatory activation of FYN and KDM4 contributes to the resistance against TKIs. FYN expression is associated with therapy resistance and persistence by demonstrating its upregulation in various experimental models of drug-tolerant persisters and residual disease following targeted therapy, chemotherapy, and radiotherapy. Collectively, our study provides novel targets and mechanistic insights that can guide the development of effective combinatorial targeted therapies, thus maximizing the therapeutic benefits of TKIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicinal Materials Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.
- Department of Biological Sciences, Korea University, Seoul, Republic of Korea.
- Division of Bio-Medical Science and Technology, Korea University of Science and Technology, Daejeon, Republic of Korea.
- Research Lab of Electronics, Massachusetts Institute of Technology, Cambridge, United States.
- Targeted Therapy Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Republic of Korea.
- College of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul, Republic of Korea.
ORCID-Profile: Tackhoon Kim
Förderung
- National Research Foundation of Korea
- Korea Institute of Science and Technology
Zitieren
APA
Kim, T., Park, B. S., Heo, S., Jeon, H., Kim, J., Kim, D., Kook Lee, S., Jung, S. Y., Kong, S. Y., & Lu, T. (2025). Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer. eLife. https://doi.org/10.7554/elife.93921
Vancouver
Kim T, Park BS, Heo S, Jeon H, Kim J, Kim D, et al. Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer. eLife. 2025. doi:10.7554/elife.93921
BibTeX
@article{Kim2025,
author = {Kim, Tackhoon and Park, Byung-Sun and Heo, Soobeen and Jeon, Heeju and Kim, Jaeyeal and Kim, Donghwa and Kook Lee, Sang and Jung, So-Youn and Kong, Sun-Young and Lu, Timothy},
title = {Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.93921}
}
EUVIMED